Amanote Research
Register
Sign In
Efficacy and Safety of Hepatitis C Direct-Acting Protease Inhibitors (DAA-PI ) in Real Life in HIV-HCV Coinfected Patients
BMC Infectious Diseases
- United Kingdom
doi 10.1186/1471-2334-14-s2-p84
Full Text
Open PDF
Abstract
Available in
full text
Categories
Infectious Diseases
Date
May 1, 2014
Authors
A Ménard
C Dhiver
I Ravaux
J Moreau
S Mokhtari
P Colson
L Meddeb
P Brouqui
A Stein
Publisher
Springer Science and Business Media LLC
Related search
Benefit of Direct-Acting Antiviral Therapy for Hepatitis C Virus (HCV) in Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia
Clinical Microbiology and Infection
Medicine
Infectious Diseases
Microbiology
Efficacy and Safety of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients Taking Proton Pump Inhibitors
Journal of Clinical and Translational Hepatology
Patient-Reported Symptoms During Direct-Acting Antiviral Treatment: A Real-Life Study in HIV-HCV Coinfected Patients (ANRS CO13 HEPAVIH)
Journal of Hepatology
Hepatology
Survival of HIV/HCV Co-Infected Patients Before Introduction of HCV Direct Acting Antivirals (DAA)
Scientific Reports
Multidisciplinary
All-Oral DAA Therapy Against HCV in HIV/HCV-coinfected Subjects in Real-World Practice: Madrid-CoRe Findings
Hepatology
Medicine
Hepatology
The Real-World Efficacy and Safety of Direct-Acting Oral Antiviral Treatment in Chronic Hepatitis C Genotype 1 Patients in Turkey
Cumhuriyet Medical Journal
Medicine
Plasma Ribavirin Trough Concentrations at Week 4 Predict Hepatitis C Virus (HCV) Relapse in HIV-HCV-Coinfected Patients Treated for Chronic Hepatitis C
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
Barriers to Treatment of Hepatitis C in HIV/HCV Coinfected Adults in Brazil
Brazilian Journal of Infectious Diseases
Infectious Diseases
Microbiology
Efficacy and Tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected Patients With Psychiatric Disorders
BMC Infectious Diseases
Infectious Diseases
